Spin-off From Pereira Lab Raises 6M Euros to Advance In vivo DC Reprogramming

Asgard Therapeutics AB, a private biotech company spin off from the Pereira Lab, announces the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Asgard Therapeutics is currently developing a ground breaking cancer immunotherapy approach to reinstate cancer immunogenicity. 

Read more here!